In the dynamic world of biotechnology, few stories reflect the blend of scientific brilliance and entrepreneurial instinct as vividly as that of Dr. Zhou Lihan. His journey from a young student discovering the allure of biology to the leader of a global diagnostics company captures a rare fusion of academic rigor, curiosity, and purpose-driven innovation. His career stands as a testament to the belief that when passion meets opportunity, groundbreaking solutions emerge for the benefit of society.
“My passion is translating science and technology to save lives that’s as simple as it is.”
– Dr. Zhou Lihan
A Spark That Began in a Classroom
Dr. Zhou often reflects on how a seemingly simple choice early in life changed everything. As a secondary school student deciding between Geography and Biology, he chose Biology, an instinctive decision that opened the door to a lifelong commitment to life sciences. That early fascination deepened through the years, ultimately guiding him toward advanced research at the National University of Singapore.
His academic path led him to complete a PhD in Biochemistry and Molecular Biology in 2012. During this time, he became increasingly drawn to the world of microRNAs, tiny molecular regulators that control gene expression and influence a vast range of biological processes. The complexity and significance of these molecules ignited his determination to develop technologies capable of detecting them with exceptional accuracy.
The Birth of an Accidental Entrepreneur
The origins of MiRXES, a company he would later co-found, stemmed from a research group at NUS that refused to let groundbreaking scientific discoveries remain confined within university walls. The team, supported by A*STAR’s institution ecosystem, had developed a highly sensitive platform capable of detecting minute genetic materials. This technological advantage revealed promising applications in early disease detection, especially cancer.
Encouraged by early proof-of-concept studies conducted with the Singapore Gastric Cancer Consortium, the team realized the meaningful impact their innovation could create in real-world healthcare. Motivated by this purpose, they transitioned from lab researchers to entrepreneurs, establishing MiRXES in 2014. Dr. Zhou often describes this shift as an “accidental journey,” guided not by business ambition but by the responsibility to bring life-saving science to more people.
The startup entered the market during a favorable season for high-tech innovation in Singapore, supported by strong government backing, growing venture capital interest, and collaborative momentum across academia and industry. In the very first week of operations, the young company secured major contracts with multinational pharmaceutical partners, an early validation of its technology and mission.
Leading a Mission of Precision Healthcare
As CEO, Dr. Zhou has played a central role in scaling MiRXES from a small research-driven spin-off to a global pioneer in RNA-powered early detection. Under his leadership, the company developed the world’s first blood test for early gastric cancer detection, GASTROClear, an achievement that transformed the clinical landscape.
His tenure also saw the development and CE-IVD certification of Fortitude Kit 2.0, a diagnostic test that became a critical tool in Singapore’s pandemic response. The success of these innovations paved the way for a US$200 million Series C funding round, accelerating global expansion across diagnostics, biomarker discovery, and manufacturing services.
Dr. Zhou attributes this progress to a leadership style rooted in collaboration. He believes in giving every team member a voice and fostering cross-functional integration. In his view, the culture of innovation flourishes only when people feel connected to a shared goal, saving lives through early, actionable, and personalized diagnostics.
Navigating Challenges in Modern Healthcare
Throughout his journey, Dr. Zhou has maintained a clear understanding of the healthcare landscape. He emphasizes that the greatest challenge facing global health systems whether in advanced or developing nations is delivering precision healthcare both affordably and reliably. Rising costs, aging populations, and regulatory complexities require innovative solutions that balance safety with accessibility.
He often explains that while genetic mutations are widely discussed, not all mutations equate to cancer. Accurate interpretation is as essential as detection. His conviction is that diagnostic tools must empower individuals with actionable insights not fear, so they can take the right next steps toward prevention or treatment.
A Vision Rooted in Hope and Action
When asked what advice should be offered to someone newly diagnosed with cancer, Dr. Zhou emphasizes hope. With advances in diagnostics and treatment, he believes cancer is steadily becoming a manageable chronic condition rather than a definitive fate. His philosophy underscores resilience: giving up hope, he says, is the moment cancer begins to win.
His personal mantra, “To know is to act,” reflects the foundational spirit of his career. Knowledge becomes meaningful only when applied. From long hours in research labs to steering a fast-growing biotech company, he remains committed to acting on ideas, learning from challenges, and pushing scientific boundaries.
The Road Ahead: Scaling RNA Innovation Globally
“To know is to act. Without action, even the most brilliant idea remains just an idea.”
– Dr. Zhou Lihan
Looking ahead, Dr. Zhou envisions MiRXES becoming a world leader in multi-cancer early detection tests and a dominant provider of specialty oncology services in Southeast Asia. His mission extends beyond organizational goals, he hopes to inspire and cultivate the next generation of scientists and innovators who will continue reshaping the diagnostics landscape.
From pioneering microRNA technologies to navigating a pandemic, his journey demonstrates how deep scientific curiosity, combined with an unwavering drive to help humanity, can transform the future of healthcare.
Magazine 